💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...
💊💉 #bevacizumab SmPC for Aybintio® 25 mg/ml concentrate for solution for infusion. has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; 5.3 Preclinical safety data; 6.6 Special precautions for disposal; Revised: 05/06/2023 SPC.AYB.23.GB.0219.3.0-4.0.NoRCN. 🌐 https://www.medicines.org.uk/emc/product/11801/smpc Change log: https://www.medicines.org.uk/emc/pro ...